ReviewPaediatric drugs2014
Drug treatment of pulmonary hypertension in children.
Review in Paediatric drugs, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pediatric Cardiac Intensive Care Society 2014 Consensus Statement: Pharmacotherapies in Cardiac Critical Care Pulmonary Hypertension.Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies · 2016Guideline
- A bosentan pharmacokinetic study to investigate dosing regimens in paediatric patients with pulmonary arterial hypertension: FUTURE-3.British journal of clinical pharmacology · 2017Trial
- Pilot study to validate endothelium collection from pulmonary artery balloon catheter in children.Pediatric research · 2026Article
- Experience with selexipag in triple therapy for pulmonary arterial hypertension in Chinese children.BMC pediatrics · 2026Article
- Navigating Pediatric Cor Pulmonale: A Comprehensive Review of Diagnosis and Management.Cureus · 2024Review
- Sildenafil during the 2nd and 3rd Trimester of Pregnancy: Trials and Tribulations.International journal of environmental research and public health · 2022Review
- Congenital Heart Disease: The State-of-the-Art on Its Pharmacological Therapeutics.Journal of cardiovascular development and disease · 2022Review
- Safety of chronic high-dose calcium channel blockers exposure in children with pulmonary arterial hypertension.Frontiers in cardiovascular medicine · 2022Article
- Lyoprotective Effects of Mannitol and Lactose Compared to Sucrose and Trehalose: Sildenafil Citrate Liposomes as a Case Study.Pharmaceutics · 2021Article
- Long-Term Survival and Causes of Death in Children with Trisomy 21 After Congenital Heart Surgery.The Journal of pediatrics · 2021Article
- Pulmonary Hypertension in Children across Africa: The Silent Threat.International journal of pediatrics · 2021Review
- Treatment of pediatric pulmonary arterial hypertension: A focus on the NO-sGC-cGMP pathway.Pediatric pulmonology · 2019Review
- Placental effects and transfer of sildenafil in healthy and preeclamptic conditions.EBioMedicine · 2019Article
- Bosentan for Treatment of Pediatric Idiopathic Pulmonary Arterial Hypertension: State-of-the-Art.Frontiers in pediatrics · 2019Review
- A Novel Therapeutic Approach in the Treatment of Pulmonary Arterial Hypertension: Allium ursinum Liophylisate Alleviates Symptoms Comparably to Sildenafil.International journal of molecular sciences · 2017Article
- Addressing the challenges of phenotyping pediatric pulmonary vascular disease.Pulmonary circulation · 2017Review
- Current Concepts in Management of Pulmonary Hypertension: Fighting the Old Demon with Modern Weapons.Indian journal of pediatrics · 2015Review
- Safety and tolerability considerations in the use of sildenafil for children with pulmonary arterial hypertension.Drug, healthcare and patient safety · 2015Review
- Efficacy and safety of tadalafil in a pediatric population with pulmonary arterial hypertension: phase 3 randomized, double-blind placebo-controlled study.Pulmonary circulationArticle
- Use of Oral Sildenafil in the Management of Persistent Pulmonary Hypertension of the Newborn: A Case Report and Review of Literature.Nigerian medical journal : journal of the Nigeria Medical AssociationReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Pulmonary arterial hypertension (PAH) is a rare disease in infants and children that is associated with significant morbidity and mortality. The disease is characterized by progressive pulmonary vascular functional and structural changes resulting in increased pulmonary vascular resistance and eventual right heart failure and death. In the majority of pediatric patients, PAH is idiopathic or associated with congenital heart disease and rarely is associated with other conditions such as connective tissue or thromboembolic disease. Although treatment of the underlying disease and reversal of advanced structural changes has not yet been achieved with current therapy, quality of life and survival have been improved significantly. Targeted pulmonary vasodilator therapies, including endothelin receptor antagonists, prostacyclin analogs, and phosphodiesterase type 5 inhibitors, have demonstrated hemodynamic and functional improvement in children. The management of pediatric PAH remains challenging, as treatment decisions continue to depend largely on results from evidence-based adult studies and the clinical experience of pediatric experts. This article reviews the current drug therapies and their use in the management of PAH in children.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.